Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma

Clinical Lymphoma and Myeloma

Volumn 6, Issue 6, 2006, Pages 475-477

  Palumbo, Antonio ^a   Avonto, Ilaria ^a   Bruno, Benedetto ^a   Falcone, Antonietta ^b   Scalzulli, Potito Rosario ^c   Ambrosini, Maria Teresa ^a   Bringhen, Sara ^a   Gay, Francesa ^a   Cavallo, Federica ^a   Falco, Patrizia ^a   Massaia, Massimo ^a   Musto, Pellegrino ^c   Boccadoro, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^c UO Oncologia Ospedale Oncologico Regionale   (Italy)

Author keywords

Febrile neutropenia; Peripheral neuropathy; Pneumonia; Prednisone; Stem cell transplantation

Indexed keywords

ANTIBIOTIC AGENT; BORTEZOMIB; DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; MALE; MYELOMA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; THROMBOCYTOPENIA; TUMOR REGRESSION;

EID: 33745923167     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2006.n.028     Document Type: Article

References (15)

1. Bruno B, Rotta M, Giaccone L, et al. New drugs for treatment of multiple myeloma. Lancet Oncol 2004; 5:430-442.
2. Hideshima T, Chauhan H, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96:2943-2950.
3. Berenson JR, Yang HH, Sadler K et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24:937-943.
4. Palumbo A, Avonto I, Bruno B, et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 2006; 76:273-277.
5. Palumbo A, Ambrosini MT, Pregno P, et al. Velcade TM plus melphalan, prednisone, and thalidomide (V-MPT) for advanced multiple myeloma. Blood 2005; 106:717a (Abstract #2553).
6. Palumbo A, Bringhen S, Musto P et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multilple myeloma: randomized controlled trial. Lancet 2006; 367:825-831.
7. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
8. Harousseau JL. Standard therapy versus autologous transplantation in multiple myeloma. Hematol Oncol North Am 1997; 11:133-146.
9. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. Blood 1999; 94:1248-1253.
10. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842-854.
11. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102:1115-1123.
12. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
13. Cancer Therapy Evaluation Program. Common terminology criteria for adverse event v 3.0. DCTD, NCI, NIH, DHHD. March 31, 2003 (http://ctep.cancer.gov). Published date: December 12, 2003.
14. Palumbo A, Bringhen S, Petrucci MT. et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104:3052-3057.
15. Rajkumar SV, Fonseca R, Lacy MQ, et al. Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant 1999; 23:1267-1272.